Global Ophthalmic Drugs Market Forecast up to 2018 – 2024

  • 104

  • 19

  • 57

  • 4 / 0
    Regions/ Countries

  • 12

  • 10
    Enquiry Hours

Overview: Ophthalmic drugs are widely used for the treatment of eye disorders such as glaucoma, conjunctivitis, cataract, dry eyes, diabetic retinopathy, and others. Development of innovative ophthalmic drug delivery methods has aided the drug manufacturers in developing effective and advanced therapeutic tactics. American Academy of Ophthalmology has stated that nearly 11 million individuals in the US are currently suffering from age-related macular degeneration (AMD), while almost 10% of that population have wet AMD. Such inclinations in eye ailments worldwide contribute to the development of the ophthalmic drugs market.

The other significant aspects that help in the improvement the market are high pervasiveness of glaucoma globally and intensification in evolution in the development of combination drugs for glaucoma. Additionally, the changing aspects in the demography worldwide are driving the growth of the market. Nevertheless, the hazard of side effects related to ophthalmic drugs and loss of patent for blockbuster drugs are hampering the market growth.

Market Analysis: The “global ophthalmic drugs market” is estimated to witness a CAGR of 6.3% during the forecast period 2018–2024. The global ophthalmic drugs market is analyzed based on indication type and regions.

Regional Analysis: The regions covered in the report are North America, Europe, Asia Pacific, and Rest of the World (ROW). North America accounts for the largest share of the ophthalmic drugs market, followed by Europe, Asia Pacific, and Rest of the World. North America alone occupies more than 35% of the market, with a significant contribution from the US to market growth.

Indication Type Analysis: Based on the Indication type, the market is segmented into dry eyes, glaucoma, eye infection/inflammation, retinal disorders, and others. The market is dominated by retinal disorders and is also expected to be the fastest growing segment. However, glaucoma is the second largest segment, owing to the high prevalence of diseases and lack of awareness among the people.

Key Players: Novartis AG, Pfizer, Allergan Inc., Valeant Pharmaceutical International, Santen Pharmaceutical Co., Ltd., Regeneron Pharmaceutical, Akron Inc., and Johnson & Johnson are the key players in the market. Shire Plc, Daiichi Sankyo, Inc., Bayer AG, F.Hoffmann-La Roche, and Sun Pharmaceuticals are the companies to watch for.

Competitive Analysis: In future, several blockbuster drugs that have dominated the market, are expected to lose their patents. The patents of successful products accounted for over $6 billion. The loss of patent is the most important aspect imposing a major threat to the leaders in the ophthalmic drugs market., Lupin Pharmaceuticals received US FDA approval on February 2015, for its bimatoprost ophthalmic solution 0.03%, the generic version of Lumigan. This affected the Allergan’s market. Formycon AG, a German biosimilars developing company is currently developing biosimilar for Eylea by Regeneron Pharmaceutical. Allergan, meanwhile, is under the threat from Akron, which is developing a generic version of Restasis. The release of such product is likely to generate a strong burden on the market players.

Benefits: The report provides complete details about the usage and adoption rate of ophthalmic drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.

Key Stakeholders:

1     Industry Outlook 

1.1        Industry Overview
1.1.1     Global Driver for Pharmaceutical Demand:
1.1.2     Pharmaceutical Spending Region Wise
1.1.3     R&D Pipeline in Pharmaceutical Industry
1.1.4     Top Pharma Drugs by Sales in 2017 ($Million)
1.2        Industry Trends
1.3        Total Addressable Market

2     Report Outline 

2.1        Report Scope
2.2        Report Summary
2.3        Research Methodology
2.4        Report Assumptions

3     Market Snapshot

3.1        Market Definition – Infoholic Research
3.2        Segmented Addressable Market
3.2.1     Trends in the Ophthalmic Drugs Market
3.3        Related Markets
3.3.1     Bacterial Conjunctivitis Drugs    Trends of Bacterial Conjunctivitis Drugs Market
3.3.2     Contact Lenses    Trends of contact lens market

4     Market Outline 

4.1        Ophthalmic Drugs Approved by FDA
4.2        Market Segmentation
4.3        Porter 5(Five) Forces
4.4        PEST Analysis

5     Market Characteristics

5.1        Market Dynamics
5.1.1     Drivers    Increasing prevalence of eye diseases    Increasing prevalence of cataract    Increasing aging population
5.1.2     Opportunities    Increasing mergers & acquisitions
5.1.3     Restraints    Complex drug development process    Loss of patent for blockbuster drugs
5.2        DRO – Impact Analysis
5.3        Key Stakeholders

6     Indication: Market Size and Analysis

6.1        Overview
6.2        Dry Eyes
6.3        Glaucoma
6.4        Eye Infection/ Inflammation
6.5        Retinal Disorder
6.6        Others

7     Regions: Market Size and Analysis

7.1        Overview
7.2        North America
7.2.1     Overview
7.3        Europe
7.3.1     Overview
7.4        Asia Pacific
7.4.1     Overview
7.5        Rest of the World
7.5.1     Overview

8     Competitive Landscape 

9     Vendor Profiles

9.1        Allergan PLC
9.1.1     Overview
9.1.2     Business Units
9.1.3     Geographic Revenue
9.1.4     Business Focus
9.1.5     SWOT Analysis
9.1.6     Business Strategies
9.2        Novartis AG
9.2.1     Overview
9.2.2     Business Units
9.2.3     Geographic Presence
9.2.4     Business Focus
9.2.5     SWOT Analysis
9.2.6     Business Strategy
9.3        Pfizer Inc.
9.3.1     Overview
9.3.2     Business Units
9.3.3     Geographic Presence
9.3.4     Business Focus
9.3.5     SWOT Analysis
9.3.6     Business Strategies
9.4        Valeant Pharmaceuticals International Inc. (Bausch Health)
9.4.1     Overview
9.4.2     Business Units
9.4.3     Geographic Presence
9.4.4     Business Focus
9.4.5     SWOT Analysis
9.4.6     Business Strategy
9.5        Santen Pharmaceutical Co., Ltd
9.5.1     Overview
9.5.2     Business Units
9.5.3     Geographic Presence
9.5.4     Business Focus
9.5.5     SWOT Analysis
9.5.6     Business Strategies
9.6        Akorn Inc.
9.6.1     Overview
9.6.2     Business Focus
9.6.3     SWOT Analysis
9.6.4     Business Strategy
9.7        Johnson & Johnson
9.7.1     Overview
9.7.2     Business Units
9.7.3     Geographic Revenue
9.7.4     Business Focus
9.7.5     SWOT Analysis
9.7.6     Business Strategies

10   Companies to Watch for

10.1     Shire plc
10.1.1  Overview
10.1.2  Highlights
10.2     Daiichi Sankyo, Inc.
10.2.1  Overview
10.2.2  Highlights
10.3     Bayer AG
10.3.1  Overview
10.4     F. Hoffmann-La Roche (Genentech)
10.4.1  Overview
10.5     Sun Pharmaceuticals
10.5.1  Overview
10.5.2  Highlights



Infoholic research works on a holistic 360° approach in order to deliver high quality, validated and reliable information in our market reports. The Market estimation and forecasting involves following steps:

  • Data Collation (Primary & Secondary)
  • In-house Estimation (Based on proprietary data bases and Models)
  • Market Triangulation
  • Forecasting

infoholic Research Methodology

Market related information is congregated from both primary and secondary sources.

Primary sources involved participants from all global stakeholders such as Solution providers, service providers, Industry associations, thought leaders etc. across levels such as CXOs, VPs and managers. Plus, our in-house industry experts having decades of industry experience contribute their consulting and advisory services.

Secondary sources include public sources such as regulatory frameworks, government IT spending, government demographic indicators, industry association statistics, and company publications along with paid sources such as Factiva, OneSource, Bloomberg among others.